Serial prescription audits and an active feedback definitely improve the prescription behaviours in the therapeutic decision making. But discontinuing the prescription audits begins to reverse the improvement in the prescription behaviours.

No abstract

CONTEXT (BACKGROUND): Dyslipidemia has been recognized as main reason for development of atherosclerosis and coronary artery disease. Statin group of drugs are most commonly prescribed for the treatment of dyslipidemia. Among them atorvastatin and relatively new drug rosuvastatin are prescribed more frequently. AIM: The aim of the study was to compare effectiveness of rosuvastatin and atorvastatin in dyslipidemia and achieving the treatment goals set by ATP III and Asian Indian Guidelines.

BACKGROUNDThe universal health coverage in developing countries including India requires access to essential medicines at affordable prices which can only be achieved with rational prescription behaviour of the prescriber. Aims-The main objective of this study was to study and compare the impact of serial prescription audits with active feedback on the prescription behaviours of the prescribers of two tertiary health care centres. Setting and Design-This is retrospective data-based cross sectional study conducted in outpatient department

AIM:To compare the efficacy of acamprosate with other drugs to decrease the severity of sensorineural tinnitus. MATERIAL AND METHOD: The study was randomised double-blind, placebo controlled, crossover. Forty adult subjects (>18 years of age), of either sex with tinnitus of sensorineural origin, were administered either acamprosate 333 mg tds or matched placebo for a period of six weeks followed by a washout period of one week. Drug therapy was switched for another six weeks in consonance with the crossover design. The effect of acamprosate and placebo on subjective relief and objective improvement was evaluated by using modified tinnitus severity quality of life scores and audiometry with tinnitus matching in frequency and loudness. RESULTS: At the end of study the drug had shown a statistically significant improvement in reducing the tinnitus score in 92.5% of the patients and placebo with an improvement in 12.5% of the patients in contrast to other drugs belonging to this group. CONCLUSION: Acamprosate is an effective drug in treating the severity of sensorineural tinnitus